Does liposomal glutathione or liposomal vitamin C absorb better than standard oral supplements?

The short answer

Evidence tier: 3 — small randomised crossover pharmacokinetic trials for vitamin C and a single small open-label comparison for glutathione; no outcome trials for either.

Liposomal glutathione and liposomal vitamin C do absorb somewhat better than standard oral forms in short human studies, but the gap is smaller and less certain than marketing suggests. For vitamin C, about ten small pharmacokinetic trials mostly show higher blood levels with liposomes. For glutathione, only one tiny head-to-head study exists, and plain oral glutathione also raised body stores in a six-month randomized trial.

The main points:

• "Better absorbed" is mostly about blood levels after a single dose, not about health outcomes.
• Liposomal vitamin C: consistent but modest gains in the best-controlled trial (about 20–27% higher peaks at 500 mg).
• Liposomal glutathione: one 12-person open-label comparison; the rest of the evidence has no plain-glutathione control.
• Many of the studies were run or funded by ingredient makers, which is common in this field but worth knowing.

What does "liposomal" mean?

Evidence tier: 5 — mechanism background drawn from general pharmaceutics; this section contains no human comparative data.

A liposome is a tiny bubble made of phospholipids, the same fats that form cell membranes. Each phospholipid has a water-loving head and two fat-loving tails. In water, they line up tail to tail into a double layer that closes into a sphere, with a small pocket of water inside. Water-soluble nutrients such as vitamin C and glutathione are carried in that inner pocket.

The idea is that wrapping a nutrient in this layer protects it from digestion and helps it cross the gut wall, possibly by fusing with or being taken up by gut cells rather than relying only on transporters. Glutathione is a tripeptide (glutamate, cysteine and glycine) that gut and liver enzymes break down, and vitamin C is absorbed through transporters that saturate at higher doses. Both are reasonable targets for this technology in theory. Oral delivery of other peptides faces the same digestion problem, covered in our non-injectable peptides guide.

Not every product labelled "liposomal" is the same. Particle size, the phospholipid source, how much of the nutrient is actually enclosed rather than floating free, and how stable the bubbles are on the shelf all vary between manufacturers. Few products publish these figures, which is one reason a result for one brand cannot be assumed for another.

The practical question is whether the theory shows up in human blood samples, and by how much.

Does standard oral glutathione absorb at all?

Evidence tier: 2 — one six-month randomized placebo-controlled trial, plus smaller conflicting studies.

The early answer was no. In a 1992 study of seven volunteers, a single 3 g oral dose of glutathione did not raise plasma glutathione over the following 270 minutes (Witschi et al., 1992). A 2011 randomized trial in 40 healthy adults taking 500 mg twice daily for four weeks found no change in oxidative stress markers or in red blood cell glutathione (Allen and Bradley, 2011).

A longer trial changed the picture. In a six-month randomized, double-blind, placebo-controlled study of 54 adults, standard oral glutathione at 250 or 1,000 mg per day raised glutathione in blood, and at the higher dose by 30–35% in red cells, plasma and lymphocytes (Richie et al., 2015). Levels returned to baseline one month after stopping. So plain oral glutathione is not useless; it seems to work slowly, over months rather than hours.

Does liposomal glutathione absorb better?

Evidence tier: 4 — a single small open-label comparison and an uncontrolled pilot study.

The most-cited liposomal study is a one-month pilot in 12 healthy adults taking 500 or 1,000 mg per day (Sinha et al., 2018). Whole-blood glutathione rose by up to 40% and levels in immune cells by up to 100% within two weeks. However, the study had no placebo group and no plain-glutathione group, so it cannot show that liposomes beat the standard form. The authors disclosed funding from a company that sells liposomal glutathione.

The only direct human comparison we found is a 2026 open-label study in which 12 people (six per group) took a single 1 g dose of either a branded liposomal product or plain glutathione (Prasad et al., 2026). Peak plasma glutathione was reported as about six times higher with the liposomal product. That is a large difference, but it comes from six people per arm, one dose, one brand and no blinding.

Does liposomal vitamin C absorb better than regular vitamin C?

Evidence tier: 3 — several small randomized crossover pharmacokinetic trials with a consistent direction, no outcome trials.

Oral vitamin C is tightly regulated by the body. In NIH studies, 1.25 g by mouth produced peak plasma levels of about 135 µmol/L versus about 885 µmol/L when given intravenously (Padayatty et al., 2004). That ceiling is the reason liposomal products exist.

The ceiling comes from absorption and the kidneys. In an NIH inpatient study, healthy volunteers were first depleted of vitamin C and then given rising daily doses. A single 200 mg dose was completely absorbed, but at higher doses bioavailability fell and the extra absorbed vitamin C was excreted in urine. Plasma was completely saturated at 1,000 mg a day, and white blood cells were saturated at just 100 mg a day (Levine et al., 1996). So for people who already eat enough vitamin C, there is limited room for any oral form to raise levels much further.

A 2025 scoping review found 10 human studies comparing liposomal and non-liposomal vitamin C, at doses from 0.15 to 10 g (Carr, 2025). Nine reported higher bioavailability with liposomes: 1.2 to 5.4 times higher peak levels and 1.3 to 7.2 times higher total exposure. The review also noted that none measured urinary elimination, only two looked at uptake into cells, and only two looked at any biological effect.

The Davis study adds one useful detail: despite higher blood levels, the liposomal form gave similar protection against oxidative stress in a lab test of blood-flow interruption as plain oral and IV vitamin C. Higher levels did not translate into a measurably different effect.

How do you read a bioavailability study?

Evidence tier: 5 — editorial explainer of standard pharmacokinetic terms, applied to the trials cited above.

Most of the studies above report three numbers from repeated blood draws after a dose:

• Cmax (peak concentration): the highest level reached. "27% higher peak" in the Purpura trial means that if plain vitamin C peaked at 100 units, the liposomal form peaked at about 127.
• AUC (area under the curve): total exposure over the sampling period. This is usually what "1.77 times the bioavailability" refers to.
• Tmax: how long it took to reach the peak.

Two reading habits help. First, a "times" figure and a percentage are easy to confuse: 1.2 times higher is 20% higher, while 5.4 times higher is 440% higher. Second, check where the measurement was taken. Plasma levels rise and fall within hours; levels in white blood cells or red cells are closer to what tissues hold, and they often move far less. In the Purpura trial, the liposomal advantage in total exposure was 21% in plasma but only 8% in white cells.

Single-dose results also say little about steady state. Richie's glutathione trial and Levine's vitamin C study both suggest that body stores after weeks of daily intake can look different from a single-dose curve.

What do the marketing claims get wrong?

Evidence tier: 5 — editorial comparison of product claims with the studies above.

Common claims include "up to 10 times better absorption", "absorbs like an IV" and "bypasses digestion". Against the evidence:

• "Like an IV": the one study that included IV vitamin C found liposomal levels well below it.
• "Up to X times": the top of the range comes from single studies of single brands; the best-blinded trial found about a quarter higher.
• Blood levels are not outcomes: no trial has shown liposomal glutathione or vitamin C improves a health outcome more than the standard form.
• Formulations differ: a result for one brand does not transfer to another, and liposome quality varies.

Limitations

This is an educational review, not medical advice.

• We read abstracts, not full texts, so details such as exact funding arrangements and dropout rates are not summarized for every study.
• Most trials are small and short, often single-dose, in healthy young adults with normal baseline levels.
• Industry involvement is common; several studies tested one branded product, and some authors work for ingredient makers.
• No study we found compared outcomes such as infections, skin or fatigue between liposomal and standard forms.

The bottom line

Liposomal delivery is not pure marketing: for vitamin C, small but well-designed trials point the same way, toward modestly higher blood levels. For glutathione, the evidence that liposomes beat the standard form rests on one 12-person study, while plain oral glutathione has the better randomized trial behind it.

What none of these studies show is that the higher numbers matter for health. If you are weighing the price premium, the honest framing is "possibly better absorbed, benefit unproven". Anyone using glutathione or high-dose vitamin C for a medical condition should discuss it with a physician.

Related on this site

• Peptides for longevity: what the evidence supports
• NAD+ and peptides as a longevity stack
• Longevity biomarkers in 2026
• Non-injectable peptides guide
• How evidence grades work
• Longevity pillar

References

• Witschi A, Reddy S, Stofer B, et al. 1992. The systemic availability of oral glutathione. Eur J Clin Pharmacol. PMID 1362956
• Allen J, Bradley RD. 2011. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. J Altern Complement Med. PMID 21875351
• Richie JP Jr, Nichenametla S, Neidig W, et al. 2015. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. PMID 24791752
• Sinha R, Sinha I, Calcagnotto A, et al. 2018. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. Eur J Clin Nutr. PMID 28853742
• Prasad KN, Chandrashekar C, Karthik Y, et al. 2026. Liposomal glutathione outperforms plain glutathione in uptake, cell regeneration and systemic availability: evidence from cellular and human models. Br J Nutr. PMID 41559937
• Levine M, Conry-Cantilena C, Wang Y, et al. 1996. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A. 93(8):3704-3709. PMID 8623000 · doi:10.1073/pnas.93.8.3704
• Padayatty SJ, Sun H, Wang Y, et al. 2004. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. PMID 15068981
• Carr AC. 2025. Do liposomal vitamin C formulations have improved bioavailability? A scoping review identifying future research directions. Basic Clin Pharmacol Toxicol. PMID 40506693
• Davis JL, Paris HL, Beals JW, et al. 2016. Liposomal-encapsulated ascorbic acid: influence on vitamin C bioavailability and capacity to protect against ischemia-reperfusion injury. Nutr Metab Insights. PMID 27375360
• Gopi S, Balakrishnan P. 2021. Evaluation and clinical comparison studies on liposomal and non-liposomal ascorbic acid (vitamin C) and their enhanced bioavailability. J Liposome Res. PMID 32901526
• Purpura M, Jäger R, Godavarthi A, et al. 2024. Liposomal delivery enhances absorption of vitamin C into plasma and leukocytes: a double-blind, placebo-controlled, randomized trial. Eur J Nutr. PMID 39237620